What is the difference between ALOGLIPTIN and Saxagliptin?

ALOGLIPTIN and Saxagliptin are both DPP-4 Inhibitors, so they work through the same broad mechanism. They differ in dosing, half-life, side-effect frequency, and how individual patients tolerate them. See the head-to-head sections below for the specifics.

Can ALOGLIPTIN and Saxagliptin be used for the same conditions?

Both medications are prescribed for overlapping indications including See full prescribing information. Always verify with your prescriber and the current FDA label before switching.

Is Alogliptin the same as Onglyza?

No. Alogliptin (ALOGLIPTIN) and Onglyza (Saxagliptin) are distinct medications. They are sometimes confused because of similar branding or because they treat overlapping conditions, but they have different active ingredients and different safety profiles.

Which has fewer side effects, ALOGLIPTIN or Saxagliptin?

Side-effect frequency varies by individual. The side-effect comparison section on this page shows FAERS-reported events for each drug side by side. FAERS is voluntary reporting, so it reflects what patients and clinicians chose to report, not absolute population risk.

Can I switch from ALOGLIPTIN to Saxagliptin?

Switching medications should always be done under prescriber supervision. The "patient stories" section on this page includes accounts from people who have made the switch and what their transition felt like, but those are individual experiences, not protocols.

ALOGLIPTIN vs Saxagliptin

Compare ALOGLIPTIN (Alogliptin) and Saxagliptin (Onglyza) — clinical data, side effects, and patient experiences.

ALOGLIPTIN

Alogliptin, Nesina, OSENI · DPP-4 Inhibitor

How it works

12.1 Mechanism of Action Increased concentrations of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are releas...

Approved for

See full prescribing information

OralTablet

Saxagliptin

Onglyza · DPP-4 Inhibitor

How it works

Inhibits DPP-4 enzyme to increase incretin levels, enhancing glucose-dependent insulin secretion and suppressing glucagon.

Approved for

Type 2 Diabetes Mellitus

FDA: 2009OralTablet

Quick Comparison

ALOGLIPTINSaxagliptin

Drug Class

DPP-4 Inhibitor

Route

Oral

Half-Life

—

FDA Approved

—

2009

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

ALOGLIPTIN

Diarrhea

1-10%

Nausea

1-10%

Vomiting

1-10%

Rash

1-10%

General Unwellness

1-10%

Shortness of Breath

1-10%

Drug Not Working

1-10%

Dizziness

1-10%

Saxagliptin

Diarrhea

1-10%

Nausea

1-10%

Drug Not Working

1-10%

Dizziness

1-10%

Headache

1-10%

Fatigue

1-10%

Weight Loss

1-10%

Vomiting

1-10%

FDA Warnings

ALOGLIPTIN

5 WARNINGS AND PRECAUTIONS Pancreatitis: There have been postmarketing reports of acute pancreatitis
1 ) Heart failure: Consider the risks and benefits of alogliptin tablets prior to initiating treatment in patients at risk for heart failure
Hypersensitivity: There have been postmarketing reports of serious hypersensitivity reactions in patients treated with alogliptin tablets such as anaphylaxis, angioedema and severe cutaneous adverse reactions, including Stevens-Johnson syndrome
3 ) Hepatic effects: Postmarketing reports of hepatic failure, sometimes fatal

Saxagliptin

Heart failure risk
Pancreatitis
Severe joint pain

Clinical Trial Data

No head-to-head clinical studies found for ALOGLIPTIN vs Saxagliptin.

ALOGLIPTIN vs Saxagliptin: What You Should Know

Key Differences

Both ALOGLIPTIN and Saxagliptin belong to the DPP-4 Inhibitor class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients.

Safety Considerations

ALOGLIPTIN carries 4 FDA warnings. Saxagliptin carries 3 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

ALOGLIPTIN vs Metformin→ALOGLIPTIN vs Semaglutide→ALOGLIPTIN vs TIRZEPATIDE→ALOGLIPTIN vs DULAGLUTIDE→ALOGLIPTIN vs LIRAGLUTIDE→ALOGLIPTIN vs EXENATIDE→

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

ALOGLIPTIN: DailyMed label · FAERS adverse events · ClinicalTrials.gov
Saxagliptin: DailyMed label · FAERS adverse events · ClinicalTrials.gov

Loading comparison data...

ALOGLIPTIN vs Saxagliptin

Compare ALOGLIPTIN (Alogliptin) and Saxagliptin (Onglyza) — clinical data, side effects, and patient experiences.

ALOGLIPTIN

Alogliptin, Nesina, OSENI · DPP-4 Inhibitor

How it works

12.1 Mechanism of Action Increased concentrations of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are releas...

Approved for

See full prescribing information

OralTablet

Saxagliptin

Onglyza · DPP-4 Inhibitor

How it works

Inhibits DPP-4 enzyme to increase incretin levels, enhancing glucose-dependent insulin secretion and suppressing glucagon.

Approved for

Type 2 Diabetes Mellitus

FDA: 2009OralTablet

Quick Comparison

ALOGLIPTINSaxagliptin

Drug Class

DPP-4 Inhibitor

Route

Oral

Half-Life

—

FDA Approved

—

2009

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

ALOGLIPTIN

Diarrhea

1-10%

Nausea

1-10%

Vomiting

1-10%

Rash

1-10%

General Unwellness

1-10%

Shortness of Breath

1-10%

Drug Not Working

1-10%

Dizziness

1-10%

Saxagliptin

Diarrhea

1-10%

Nausea

1-10%

Drug Not Working

1-10%

Dizziness

1-10%

Headache

1-10%

Fatigue

1-10%

Weight Loss

1-10%

Vomiting

1-10%

FDA Warnings

ALOGLIPTIN

5 WARNINGS AND PRECAUTIONS Pancreatitis: There have been postmarketing reports of acute pancreatitis
1 ) Heart failure: Consider the risks and benefits of alogliptin tablets prior to initiating treatment in patients at risk for heart failure
Hypersensitivity: There have been postmarketing reports of serious hypersensitivity reactions in patients treated with alogliptin tablets such as anaphylaxis, angioedema and severe cutaneous adverse reactions, including Stevens-Johnson syndrome
3 ) Hepatic effects: Postmarketing reports of hepatic failure, sometimes fatal

Saxagliptin

Heart failure risk
Pancreatitis
Severe joint pain

Clinical Trial Data

No head-to-head clinical studies found for ALOGLIPTIN vs Saxagliptin.

ALOGLIPTIN vs Saxagliptin: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.